Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Battle of the bacteria: which drug combo wins against resistant h. pylori?

NCT ID NCT03431688

Disease control Sponsor: Kangdong Sacred Heart Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two different drug combinations in 782 people with H. pylori infection that was resistant to the antibiotic clarithromycin. One group received a triple therapy with a proton pump inhibitor, amoxicillin, and metronidazole, while the other received a quadruple therapy with a proton pump inhibitor, bismuth, metronidazole, and tetracycline. The goal was to see which combination better eradicated the bacteria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metronidazole-based triple therapy (PPI, amoxicillin, metronidazole) and bismuth-based quadruple therapy (PPI, bismuth, metronidazole, tetracycline)
What this could lead to
If successful, this could identify a more effective treatment for people with drug-resistant H. pylori, reducing infection and related complications.
What could go wrong
This is a completed trial, but results may not apply to all populations. Drug resistance patterns vary, and side effects from the medications can occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

782 people

The number who actually took part.

Started

Oct 2018

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * peptic ulcer disease * H. pylori gastritis * low grade MALT lymphoma Exclusion Criteria: * history of gastric cancer surgery * severe comorbidity (ESRD, LC) * hypersensitivity to drug * pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease MALT lymphoma peptic ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori infection

Contacts and locations

Locations

  • Kangdong Sacred Heart Hospital

    Seoul, 134-701, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.